Ligachem Bio Receives Milestone Payment for LCB97; "Over 10% of Sales"
Ligachem Bio announced on July 9 that it has received a milestone payment following the first patient dosing of 'LCB97', which was out-licensed to Ono Pharmaceutical.
Due to confidentiality clauses in the contract, the amount received has not been disclosed. However, the milestone payment exceeds 10% (ten percent) of Ligachem Bio's consolidated sales of approximately KRW 141.5 billion last year, making it subject to mandatory disclosure.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
If future clinical trials, approvals, or commercialization do not materialize, the technology transfer agreement may be terminated. However, even if the contract is terminated, there is no obligation to return the milestone payment.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.